post-marketing surveillance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
== Available forms == The abuse-deterring effects of atropine when used as an adulterant are reasonably effective in reducing the combination's potential for recreational use. It combines the mechanisms of naloxone and paracetamol (the two more commonly used abuse-deterring agents) by increasing the likelihood of the overdose resulting in harmful and/or fatal sequelae (as does paracetamol), in addition to reliably producing unpleasant side-effects which "spoil" the opioid euphoria and discourage abusers from overdosing again following their initial experience (as does naloxone). This does not deter the use of single doses of difenoxin to potentiate another opiate, the anticholingeric activity of a single tablet is actually likely to increase the pleasurable effects of opioid use in a manner similar to combining one or more opioids with orphenadrine.
On 4 February 2020, US Secretary of Health and Human Services Alex Azar published a notice of declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID‑19, covering "any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID‑19, or the transmission of SARS-CoV-2 or a virus mutating therefrom", and stating that the declaration precludes "liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct". The declaration is effective in the United States through 1 October 2024. In the European Union, the COVID‑19 vaccines are licensed under a Conditional Marketing Authorisation which does not exempt manufacturers from civil and administrative liability claims. While the purchasing contracts with vaccine manufacturers remain secret, the manufacturers remain liable even for side-effects not known at the time of licensure. Pfizer has been criticised for demanding far-reaching liability waivers and other guarantees from countries such as Argentina and Brazil, which go beyond what was expected from other countries such as the US (above).
=== Evolution of mental illness representation in film === An overused trope used in film and television is depicting villains or murderers as mentally ill. This trope has evolved throughout the history of filmmaking and cinema. First introduced in the early 1900s, films like Dr. Mabuse, the Gambler (1922) and The Black Cat (1934) depicted the mentally ill villains as mad, evil doctors. Then, with the rise of Alfred Hitchcock films, he introduced the serial killer in Psycho (1960), whose character trope was subsequently used in films like Homicidal (1961), Maniac (1963), Paranoiac (1963), and Nightmare (1963). The 1970s and 1980s brought the popular "slasher" film genre, introducing iconic horror characters such as Michael Myers, Jason, and Freddy Kruger from the franchises Halloween, Friday the 13th, and A Nightmare on Elm Street, respectively.
Sources: en.wikipedia.org
== Research and publications == Kalra has emphasised the importance of person-centred care for over a decade through his reviews, research, and communications in various national and international journals. One of his earlier citations on this topic dates back to a paper he led in 2013, in which he described the role of a person-centred approach during insulin initiation and intensification—one of the most challenging aspects of diabetes management.79 Although a substantial body of his work has focused on diabetes,77,79 he has also applied the principles of person-centred care to other chronic metabolic disorders, including obesity, hypogonadism, and hypothyroidism.78 Kalra has written on menopause distress and late-onset male hypogonadism, simplifying their definitions and describing person-centric thresholds, targets, tools, and techniques for management.167,168 He is also the lead author of a paper titled Thyroid Tantrums in Teenagers, which highlights the variability in endocrine presentations during adolescence and addresses management, assessment, testing techniques, associated biomedical illness, and training. His work extends across all age groups; for instance, he has published geriatric goalposts on independence and interdependence, emphasising the importance of person-centric care in older adults. Key principles of person-centred care highlighted in Kalra's publications include effective communication with patients.65,102 Other core principles include ensuring that therapy is affordable and that the management plan is feasible for the patient.
The society – which only admitted men at the time – initially mistook Benett for a man due to her reputation as a scientist and her unusual first name, addressing her diploma of admission to "Dominum" (Master) Benett. 1840: Scottish fossil collector and illustrator Lady Eliza Maria Gordon-Cumming invited geologists Louis Agassiz, William Buckland and Roderick Murchison to examine her collection of fish fossils. Agassiz confirmed several of Gordon-Cumming's discoveries as new species. 1843: During a nine-month period in 1842–43, English mathematician Ada Lovelace translated Luigi Menabrea's article on Charles Babbage's newest proposed machine, the Analytical Engine. With the article, she appended a set of notes. Her notes were labelled alphabetically from A to G. In note G, she describes an algorithm for the Analytical Engine to compute Bernoulli numbers. It is considered the first published algorithm ever specifically tailored for implementation on a computer, and Ada Lovelace has often been cited as the first computer programmer for this reason. The engine was never completed, so her program was never tested. 1843: British botanist and pioneering photographer Anna Atkins self-published her book Photographs of British Algae, illustrating the work with cyanotypes. Her book was the first book on any subject to be illustrated by photographs. 1846: British zoologist Anna Thynne built the first stable, self-sustaining marine aquarium.
Glass noodles, or fensi (traditional Chinese: 粉絲; simplified Chinese: 粉丝; pinyin: fěnsī; lit. 'flour thread'), sometimes called cellophane noodles, are a type of transparent noodle made from starch (such as mung bean starch, potato starch, sweet potato starch, tapioca, or canna starch) and water. They originated in China. A stabilizer such as chitosan or alum (illegal in some jurisdictions) may also be used. They are generally sold in dried form, soaked to reconstitute, then used in soups, stir-fried dishes, or spring rolls. They are called "glass noodles" because of their glass-like transparency when cooked. Glass noodles are not the same as rice vermicelli, which is made from rice and white in color rather than clear (after cooking in water).
A tripeptide is a peptide derived from three amino acids joined by two or sometimes three peptide bonds. As for proteins, the function of peptides is determined by the constituent amino acids and their sequence. In terms of scientific investigations, the dominant tripeptide is glutathione (γ-L-Glutamyl-L-cysteinylglycine), which serves many roles in many forms of life.
Sources: en.wikipedia.org
Subdermal hematoma (under the skin) Intramuscular hematoma (inside muscle tissue) Skull/brain: Subgaleal hematoma – between the galea aponeurosis and periosteum Cephalohematoma – between the periosteum and skull. Commonly caused by vacuum delivery and vertex delivery. Epidural hematoma – between the skull and dura mater Subdural hematoma – between the dura mater and arachnoid mater Subarachnoid hematoma – between the arachnoid mater and pia mater (the subarachnoid space) Othematoma – between the skin and the layers of cartilage of the ear Breast hematoma (breast) Perichondral hematoma (ear) Perianal hematoma (anus) Subungual hematoma (nail) Rectus sheath hematoma Genital hematoma
Sanlúcar is a summer tourist destination famous for its cuisine, especially manzanilla (a variety of fino sherry) and prawns. It is internationally renowned for beach horse racing and flamenco music. Less well known but equally important are the historical archives of the House of Medina Sidonia (Archivo de la Casa de Medina Sidonia); the major part of the patrimony of the House of Medina Sidonia is located in the palace of the same name. The patron saint of the city is Our Lady of Charity, to whom it was dedicated in 1917.
The Roman mythographer Julius Pollux, writing in the 2nd century AD, recounts that the purple dye was first discovered by Heracles (Greek counterpart of the titular god of Tyre, Melqart) while being in Tyre to visit his beloved Tyros, or rather, by his dog, whose mouth was stained purple after biting into a snail on the beach. This story was depicted by Peter Paul Rubens in his painting Hercules' Dog Discovers Purple Dye. According to John Malalas, the incident happened during the reign of the legendary King Phoenix of Tyre, the eponymous progenitor of the Phoenicians, and therefore he was the first ruler to wear Tyrian purple and legislate on its use. Recently, the archaeological discovery of substantial numbers of Murex shells on Crete suggests that the Minoans may have pioneered the extraction of Imperial purple centuries before the Tyrians. Dating from collocated pottery suggests the dye may have been produced during the Middle Minoan period in the 20th–18th century BC. Accumulations of crushed murex shells from a hut at the site of Coppa Nevigata in southern Italy may indicate production of purple dye there from at least the 18th century BC. Additional archaeological evidence can be found from samples originating from excavations at the extensive Iron Age copper smelting site of "Slaves' Hill" (Site 34), which is tightly dated by radiocarbon to the late 11th–early 10th centuries BC. Findings from this site include evidence of the use of purple dye found in stains used on pot shards.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.